Palbocent - Palbociclib 125 mg Capsules
Palbocent - Palbociclib 125 mg Capsules
Indications
Palbociclib is a refined kinase inhibitor exquisitely tailored for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. It is prescribed in combination with:
An aromatase inhibitor as the initial endocrine-based therapy for postmenopausal women.
Fulvestrant for women experiencing disease progression following prior endocrine therapy.
Therapeutic Class
Targeted Cancer Therapy
Pharmacology
Harnessing the synergistic power of Palbociclib and antiestrogens, our meticulously crafted combination therapy targets breast cancer cells with precision. This distinguished duo results in decreased retinoblastoma protein (RB) phosphorylation, culminating in reduced E2F expression and signaling and culminating in a sophisticated growth arrest mechanism.
In vitro treatment of ER-positive breast cancer cell lines with this potent combination not only induces increased cell senescence but maintains its efficacy for up to six days post-treatment. In visionary in vivo studies utilizing patient-derived ER-positive breast cancer xenografts, the combination of Palbociclib and letrozole showcased enhanced inhibition of RB phosphorylation, significant disruption of downstream signaling, and notable suppression of tumor growth over each drug administered individually.
Embrace the elegance of precision oncology with Palbociclib, meticulously designed to redefine advanced breast cancer therapy with luxury and efficacy.
Ask Price